Results 211 to 220 of about 1,399,894 (283)

Nationwide trends in pediatric hospitalizations for eating disorders in France between 2013 and 2022: a retrospective study using the national health insurance database. [PDF]

BMC Med
Logeais E, Troussier F, Lamer A, Hendrickx M, Levaillant M, Khendek L.   +5 more
europepmc   +1 more source

Exposure to Occupational Inhalants and the Risk of Developing Rheumatoid Arthritis: A Systematic Review and Meta‐Analysis

Arthritis &Rheumatology, EarlyView.
Objective Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint pain, swelling, and stiffness. Although smoking is a well‐established risk factor for RA, the role of occupational inhalants in RA development is less well recognized.
Qianwen Liu, Xin Song, Emily Mauro, Yuan Jiang, Klementy Shchetynsky, Lars Klareskog, Lars Alfredsson, Xia Jiang   +7 more
wiley   +1 more source

Risk Factors for Heterotopic Ossification in Traumatic Brain Injury: An Analysis of the Korean National Health Insurance Service Data. [PDF]

Yonsei Med J
Yoon SY, Lim H, Cha JM, Lee SC, Lee JW.
europepmc   +1 more source

Serious Infections in Offspring Exposed to Tumor Necrosis Factor Inhibitors During Pregnancy: Comparison of Timing During Pregnancy and Placental Transfer Ability

Arthritis &Rheumatology, EarlyView.
Objective We evaluated serious infection risk in offspring exposed to tumor necrosis factor inhibitors (TNFi) in utero, separated by TNFi timing and placental transfer ability. Methods Using MarketScan (2011–2021), we identified offspring born to mothers with chronic inflammatory diseases.
Leah K. Flatman, Sasha Bernatsky, Yvan St‐Pierre, Marie‐Eve Beauchamp, Isabelle Malhamé, Anick Bérard, Évelyne Vinet   +6 more
wiley   +1 more source

Patient satisfaction with the components of the National Health Insurance Program of Nepal: a cross-sectional study. [PDF]

BMC Health Serv Res
Karmacharya BM, Marasini S, Sharma S, Adhikari M, Pandey S, Shrestha RM, Jnawali SP, Baral U, Koju P, Xu DR.   +9 more
europepmc   +1 more source

Defining Optimally Safe and Effective Blood Levels of Hydroxychloroquine in Lupus: An Important Step toward Precision Drug Monitoring

Arthritis &Rheumatology, Accepted Article.
Background Using hydroxychloroquine (HCQ) dose of 5 mg/kg/day in systemic lupus erythematosus (SLE) is associated with a higher risk of flares; HCQ blood level monitoring could be a better way to adjust HCQ dose. We studied the upper threshold for a reference range of HCQ levels to inform routine monitoring.
Shivani Garg, Benoît Blanchet, Yann Nguyen, Fauzia Hollnagel, Ada Clarke, Michelle Petri, Murray B. Urowitz, John G. Hanly, Caroline Gordon, Sang‐Cheol Bae, Juanita Romero‐Diaz, Jorge Sanchez‐Guerrero, Ann E. Clarke, Sasha Bernatsky, Daniel J. Wallace, David A. Isenberg, Anisur Rahman, Joan T. Merrill, Paul R. Fortin, Dafna D. Gladman, Ian N. Bruce, Ellen M. Ginzler, Mary Anne Dooley, Rosalind Ramsey‐Goldman, Susan Manzi, Andreas Jönsen, Graciela S. Alarcón, Ronald F. Van Vollenhoven, Cynthia Aranow, Véronique Le Guern, Meggan Mackay, Guillermo Ruiz‐Irastorza, S. Sam Lim, Murat Inanc, Kenneth C. Kalunian, Søren Jacobsen, Christine A. Peschken, Diane L. Kamen, Anca Askanase, Jill Buyon, Julie Chezel, Alicja Puszkiel, Nathalie Costedoat‐Chalumeau   +42 more
wiley   +1 more source

Use of the National Health Insurance among beneficiaries in Maluku province, Indonesia: a cross-sectional analysis of the 2021 social health insurance sample data. [PDF]

BMJ Open
Titaley CR, Ariawan I, Wahyuningsih W, Iwan RF, Malakauseya MLV, Kimberly VD, Tando Y.   +6 more
europepmc   +1 more source

Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: the Randomized, Phase 3, TULIP‐SC Study

Arthritis &Rheumatology, Accepted Article.
Objective The multinational, phase 3, double‐blind, placebo‐controlled TULIP‐SC trial evaluated the efficacy and safety of subcutaneous anifrolumab in adults who have moderate‐to‐severe SLE activity, despite receiving standard therapy. Methods Adults with SLE received subcutaneous anifrolumab 120 mg or placebo once weekly for 52 weeks (1:1 ...
Susan Manzi, Ian N. Bruce, Eric F. Morand, Richard Furie, Yoshiya Tanaka, Kenneth C. Kalunian, Anca Askanase, Patricia Puzio, Emon Khan, Jenny Wissmar, Michael Song, Catharina Lindholm, The TULIP‐SC investigators   +12 more
wiley   +1 more source

Impact of the COVID-19 pandemic on the utilization of healthcare

Journal of the Formosan Medical Association
Chung-liang Shih, Oliver Liu, You-Jun Lin   +2 more
doaj   +1 more source

Can Indonesia achieve universal health coverage? Organisational and financing challenges in implementing the national health insurance system.

SSM Health Syst
Susilo D, Wulandari LPL, Sukmayeti E, Asante A, Jan S, Thabrany H, Tangcharoensathien V, Wiseman V, Liverani M.   +8 more
europepmc   +1 more source